Product name

Summary

Organization name

Profile

A novel ex vivo method for immediate early diagnosis and prognosis of proliferative diabetic retinopathy (DRP) is provided with DRPevader.

DRPevader is based on the analysis of expression and activity of very few genes which can simply be determined using whole blood or a blood component. Therefore, DRPevader is the diagnostic link between the alteration of leukocyte gene expression, the activity of specific serum-markers, and proliferative DRP.

Commercial opportunity

DRP is the leading cause of visual loss in diabetic patients, also affecting the young diabetic population. There is a need for a reliable prediction of the risk to develop proliferative DRP, for early diagnosis of DRP as well as to estimate the probability of DRP progression.

DRPevader is able to address those issues in a quite simple fashion: Gene expression data on the one hand and activity data on the other hand are set into correlation to determine the specific risk factor of the individual patient. All data can be generated from blood components using state of the art methodology without the necessity to analyze a lot of genes or factors. For DRPevader, a focus on three to five specific genes and two factor activities is sufficient.

Therefore, DRPevader offers the possibility to develop and market a reliable diagnostic kit for DRP.  

Benefits

• Prediction, diagnosis, and progression of proliferative diabetic retinopathy
• Early stage diagnosis
• Few parameter test with standard methodology
• Blood-based testing
• World-wide IP-coverage possible

This technology is offered by PROVendis the transfer office of the state of Northrhine-Westfalia.

Contact 

Kordula Kruber, Dipl.-Biol.
Tel.: +49 (0) 208/94105-30
kk(at)provendis.info

About PROvendis

PROvendis offers companies certified and patented innovations from 24 North Rhine-Westphalian universities. The core function of the enterprise is to market patentable and commercially exploitable inventions. PROvendis GmbH was founded in 2001 as a wholly owned subsidiary of Zenit GmbH, a management consultancy firm in cooperation with the state of North Rhine-Westphalia. Since January of 2002, PROvendis has been the service provider for the universities of the state of North Rhine-Westphalia. Within the scope of the BMBF commercialization campaign, the Federal Ministry for Education and Research (BMBF) supports the activities of PROvendis.

Description File

URL

Your feedback

back